A phase I/II trial of interleukin-15--stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors

A Pérez-MartínezM A Díaz


Preliminary data suggest that T-cell-depleted haplo-identical stem cell transplantation (haplo-SCT) has a clinically beneficial allograft-versus-tumor effect associated with natural killer (NK) cell immune reconstitution. This phase I/II trial descriptively evaluates the feasibility of interleukin (IL)-15-stimulated NK cell infusion after haplo-SCT in pediatric patients with refractory solid tumors. Six patients received an IL-15-stimulated NK cell infusion at 30 days after haplo-SCT. The mean number of infused NK cells per product was 11.3 × 10(6)/kg (range, 3-27 × 10(6)/kg). The T-cell count was <1 × 10(3)/kg in all patients (range, 0-0.75 × 10(3)/kg). No toxic effects related to IL-15--stimulated NK cell infusion were observed. Four of the six patients showed a clinical response (one achieved very good partial remission, two achieved partial remission and one had stable disease). One patient had progressive disease, and the response was not evaluated in the remaining patient. After a median follow-up period of 310 days, all patients had died: four of cancer relapse, one of cancer-associated thrombotic micro-angiopathy and one of acute graft-versus-host disease. The adoptive transfer of allogeneic IL-15--stimulated NK cells m...Continue Reading


Feb 1, 1981·Transplantation·M IntronaA Mantovani
Apr 27, 1997·Transplantation·E PeterssonG Hedlund
Jun 15, 2004·Gene·Annalise M MartinFrank T Christiansen
Oct 23, 2004·Best Practice & Research. Clinical Haematology·Loredana RuggeriAndrea Velardi
Nov 6, 2004·Blood Cells, Molecules & Diseases·Ulrike KoehlDirk Schwabe
Mar 6, 2007·Immunologic Research·Q YangP H Basse
Jan 15, 2008·Transplantation·Lu-En WaiSheri M Krams
Jan 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey E RubnitzWing Leung
Jun 15, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Duck ChoDario Campana
Jun 16, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ruth LadensteinHeribert Jürgens
Aug 26, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Kinya OhataShinji Nakao
Oct 5, 2010·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·D N EissensI Joosten
Oct 23, 2010·PloS One·Olivier MorteauChristopher A O'Callaghan
Jan 18, 2011·Cancer Immunology, Immunotherapy : CII·Emilie P BuddinghArjan C Lankester
Sep 20, 2011·Best Practice & Research. Clinical Haematology·Patrick SchlegelPeter Lang
Mar 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rainer StorbBrenda M Sandmaier
Apr 30, 2013·Frontiers in Oncology·Lucia FernándezAntonio Pérez-Martínez
Dec 10, 2013·Hematology·Jeffrey S Miller
Nov 2, 2014·Expert Review of Clinical Immunology·Thomas A Waldmann
Nov 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kevin C ConlonThomas A Waldmann

❮ Previous
Next ❯


Apr 21, 2016·Journal for Immunotherapy of Cancer·Steven K GrossenbacherWilliam J Murphy
Aug 30, 2017·International Journal of Molecular Sciences·Beatriz Martín-AntonioAlvaro Urbano-Ispizua
Jan 2, 2019·Cancers·Seila Lorenzo-HerreroSegundo Gonzalez
Aug 20, 2019·Immunotherapy·Faezeh GhaemdoustNima Rezaei
Aug 20, 2016·Nature Immunology·Camille GuillereyMark J Smyth
May 6, 2017·Immunotherapy·Steven K GrossenbacherWilliam J Murphy
Mar 22, 2019·Archives of Pharmacal Research·Nayoung KimHun Sik Kim
May 28, 2020·Frontiers in Immunology·Kevin O McNerneyHamid Bassiri
Jul 27, 2018·Frontiers of Medicine·Fang FangZhigang Tian
Feb 26, 2019·Frontiers in Oncology·Gaurav NayyarMitchell S Cairo
Jun 26, 2020·Frontiers in Cell and Developmental Biology·Daria S ChulpanovaValeriya V Solovyeva
Aug 21, 2019·Frontiers in Immunology·Maria VelaAntonio Pérez-Martínez
Jul 1, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lucía FernándezAntonio Pérez-Martínez
Dec 6, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey S MillerKevin C Conlon
Jan 1, 2021·International Immunopharmacology·Shuling ZhangFengping Shan
Oct 31, 2020·Signal Transduction and Targeted Therapy·Yuqing CaoFeng Xu
Feb 7, 2021·Cancers·Martina MolgoraMarco Colonna
Dec 17, 2020·Cancers·Mieszko LachotaKarl-Johan Malmberg
Feb 6, 2021·Cancers·Adrián FernándezAntonio Pérez-Martínez
Mar 21, 2021·Scientific Reports·Iñigo TerrénFrancisco Borrego

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.